<DOC>
	<DOC>NCT02776215</DOC>
	<brief_summary>Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents.</brief_summary>
	<brief_title>Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Smith-Magenis Syndrome</mesh_term>
	<mesh_term>Sleep Disorders, Circadian Rhythm</mesh_term>
	<criteria>1. Males or females who are legally blind [defined as having a visual acuity of 20/200 or less in the betterseeing eye with best conventional correction (glasses or contact lenses) and/or a visual field of 20 degrees or less in the betterseeing eye], 3 to &lt;18 years of age or males and females with SMS and 3 to &lt;16 years of age with a nighttime sleep complaint and 3 to &lt;18 years of age or males and females with ASD and 3 to &lt;18 years of age with a nighttime sleep complaint; 2. Weigh at least 16 kg; 3 Diagnosis of SMS determined by a prior positive genetic test result as indicated by parent/guardian; Diagnosis of ASD as indicated by parent/guardian; or a diagnosis of Non24 as determined by DSM5 diagnostic criteria for the Circadian rhythm sleepwake disorder, Non24hour sleepwake hour type: 1. A persistent or recurrent pattern of sleep disruption that is primarily due to an alteration of the circadian system or to a misalignment between the endogenous circadian rhythm and the sleepwake schedule required by an individual's physical environment or social or professional schedule; 2. The sleep disruption leads to excessive sleepiness or insomnia, or both; 3. The sleep disturbance causes clinically significant distress or impairment in social, occupational, and other important areas of functioning. 1. For blind subjects only: Subjects who have a probable diagnosis of a current sleep disorder other than Non24Hour SleepWake Disorder that is the primary cause of the sleep disturbance based on clinical investigator medical judgment; 2. For blind subjects only: History (within the 12 months prior to screening) of psychiatric disorders including ADHD, Neurodisabilities, Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder, that is not being successfully treated or has not been resolved and that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures; 3. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>